Profesionales

  • Noticias profesionales

Enrique Ruiz: “La carrera profesional tendrá un reconocimiento económico”

  • Noticias profesionales

SESCAM convoca 5.405 plazas para el concurso de traslados correspondiente a 2017

  • Noticias profesionales

Los médicos acuerdan iniciar movilizaciones durante el primer trimestre de 2018

  • Noticias profesionales

CESM rechaza que se obligue a los MIR a seguir un tiempo en la Sanidad pública

  • Noticias profesionales

Las pruebas de la OPE de Valencia para 19 especialidades comienzan el 13 de enero

  • Noticias profesionales

Los médicos piden aumentar las plantillas de los centros de salud

Ver más

Nuevo en Enfermería

  • The ASCO Post
  • 1 comentario

ASH 2017: Direct Oral Anticoagulant May Reduce Recurrence of VTE in Patients With Cancer

New results from a large pilot trial suggest that direct oral anticoagulants—newer blood thinners administered as a daily pill—could be a safe and beneficial alternative for treating venous thromboembolism (VTE) in selected patients with cancer. These findings were presented by Young et al.

  • The ASCO Post
  • 1 comentario

SABCS 2017: Postmenopausal Women Who Lose Weight May Have Reduced Breast Cancer Risk

Postmenopausal women who lose weight may have a significantly reduced chance of developing breast cancer, according to new data presented by Chlebowski et al. Unlike earlier investigations of the association, this prospective study utilized a short-term, 3-year period of measured body weight and height followed by a long period of follow-up.

  • The ASCO Post
  • 1 comentario

ASH 2017: RESONATE-2 Trial: Patient-Reported Outcomes on Ibrutinib Treatment in Patients With CLL

The 3-year follow-up data from the RESONATE-2 study found that patients with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma reported sustained improvements in the measures of well-being with ibrutinib vs chemotherapy with chlorambucil.

  • The ASCO Post
  • 1 comentario

ASH 2017: Sustained Benefit With Ibrutinib in Relapsed or Refractory Mantle Cell Lymphoma

The results of a pooled analysis of patients with relapsed or refractory mantle cell lymphoma treated with ibrutinib were presented at ASH 2017. The extended follow-up data demonstrated that patients treated with ibrutinib earlier (after first relapse) experienced the best clinical outcomes in terms of both efficacy and tolerability. 

  • The ASCO Post
  • 1 comentario

SABCS 2017: 2 Years of Extended Anastrozole Therapy Proved as Effective as 5 Years in Hormone Receptor–Positive Breast Cancer

Postmenopausal women with hormone receptor–positive breast cancer who took the aromatase inhibitor anastrozole for 2 years after an initial 5 years of adjuvant endocrine therapy received an equal benefit to those who took the drug for 5 additional years. The trial results suggest that a shorter duration of treatment may provide sufficient benefits while protecting women from harmful side effects, according to data from the ABCSG-16 trial presented by Gnant et al.

  • The ASCO Post
  • 1 comentario

SABCS 2017: SOLD Trial Data Support Current Standard 12-Month Adjuvant Trastuzumab for HER2-Positive Breast Cancer

Disease-free survival after 9 weeks of adjuvant trastuzumab and standard chemotherapy was not comparable to disease-free survival after 12 months of adjuvant trastuzumab and standard chemotherapy for women with early-stage HER2-positive breast cancer, supporting the current practice of extended trastuzumab treatment, according to data from the phase III Synergism or Long Duration (SOLD) clinical trial, presented by Joensuu et al.

  • The ASCO Post
  • 1 comentario

SABCS 2017: Phase III EMBRACA Trial Meets Primary Endpoint

Patients with advanced HER2-negative breast cancer with germline <em>BRCA</em> mutations had significantly prolonged progression-free survival when treated with the poly(ADP-ribose) polymerase inhibitor talazoparib, compared with those who received chemotherapy of physician’s choice, according to data from the phase III EMBRACA trial presented by Litton et al.

  • The ASCO Post
  • 1 comentario

SABCS 2017: Older Women With Hormone Receptor–Positive Breast Cancer May Receive Similar Benefit From CDK4/6 Inhibitors as Younger Women

Older women with hormone receptor–positive, HER2-negative metastatic breast cancer who were treated with cyclin-dependent kinase 4/6 inhibitors achieved progression-free survival at a rate similar to that of younger women, according to data presented by Singh et al.

  • The ASCO Post
  • 1 comentario

SABCS 2017: Circulating Tumor Cells May Predict Late Recurrence in Patients With Hormone Receptor–Positive Breast Cancer

Among patients with hormone receptor–positive HER2-negative stage II–III breast cancer without clinical evidence of recurrence, those who had circulating tumor cells detected in blood 5 years after diagnosis had an increased risk for late recurrence of breast cancer, according to data presented by Sparano et al.

  • The ASCO Post
  • 1 comentario

SABCS 2017: MONALEESA-7: Ribociclib Improved Progression-Free Survival for Pre- and Perimenopausal Women With HR-Positive Advanced Breast Cancer

Adding ribociclib to standard endocrine therapy with temporary ovarian suppression significantly improved progression-free survival for pre- and perimenopausal women with advanced hormone receptor (HR)-positive, HER2-negative breast cancer, according to data from the MONALEESA-7 trial presented by Tripathy et al.

  • The ASCO Post
  • 1 comentario

SABCS 2017: Acupuncture May Reduce Joint Pain Caused by Aromatase Inhibitor Treatment

Acupuncture significantly reduced joint pain for postmenopausal women with early-stage breast cancer receiving treatment with an aromatase inhibitor compared with both sham acupuncture and no treatment, according to data from the randomized, phase III SWOG S1200 trial presented by Hershman et al.

  • The ASCO Post
  • 1 comentario

SABCS 2017: Combination of Pembrolizumab and Trastuzumab Shows Early Promise for Patients With Trastuzumab-Resistant Breast Cancer

A combination of pembrolizumab and trastuzumab tested in patients with trastuzumab-resistant advanced HER2-positive breast cancer was well tolerated and had clinical benefit in patients whose tumors were positive for a biomarker for pembrolizumab, according to data presented from the phase Ib/II PANACEA trial by Loi et al.

Twitter y la detección de estados de ánimo.
  • Médicos e Internet
  • 1 comentario

Twitter y la detección de estados de ánimo.

Twitter es mucho más que una red social. Sus fundadores prefieren que sea entendido como un medio de comunicación, en el que millones de usuarios cuentan lo que les pasa en cada minuto. Por tanto, cualquier tuit puede contener rasgos semánticos que sean la expresión de un determinado estado de ánimo. Surge la tentación de diseñar sistemas para detectar si determinados usuarios o grupos de usuarios pueden presentar disfunciones mentales.

  • The ASCO Post
  • 1 comentario

SABCS 2017: Adjuvant Trastuzumab Did Not Improve Outcomes for Patients With HER2-Low Breast Cancer

Adding trastuzumab to standard adjuvant chemotherapy did not improve invasive disease–free survival for patients with early-stage breast cancer found to have low levels of HER2, according to data from the randomized, phase III NSABP B-47 clinical trial presented by Fehrenbacher et al.